Carlos Gomez-Roca

16PUBLICATIONS
239CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsAllergyCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Apr 09, 2026
Simlukafusp alfa (FAP-IL2v) plus atezolizumab with or without bevacizumab in unresectable, metastatic renal cell carcinoma: a randomized, open-label phase Ib study.

Jose Luis Perez-Gracia, Begoña Mellado, Aaron Richard Hansen

|Feb 26, 2026
Lenvatinib plus Pembrolizumab for Patients with Previously Treated Advanced Gastric, Biliary Tract, or Pancreatic Cancer: Results from the Phase II LEAP-005 Study.

Mariano Ponz-Sarvisé, Sun Young Rha, Carlos A Gomez-Roca

|Jan 21, 2026
Innovative Research Organization to Facilitate Clinical Trials Implementation in the Era of Molecular Oncology: The Spiderweb Model of the Oncodistinct Network.

Simon Nannini, Anthony Goncalves, Carlos Gomez-Roca

|Jun 11, 2025
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas.

Kevin J Harrington, Stephane Champiat, Joshua D Brody

|Apr 08, 2025
Broad versus limited gene panels to guide treatment in patients with advanced solid tumors: a randomized controlled trial.

Olivier Trédan, Damien Pouessel, Nicolas Penel

|Dec 13, 2024
Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined with Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.

Jason J Luke, Karen Gelmon, Lillian L Siu

Pageof 3

Frequent Collaborators

3 joint publications

Jehad Charo

3 joint publications

Stephane Champiat

2 joint publications

Aaron Richard Hansen

2 joint publications

Debbie Robbrecht